- Xoma Corp's Neuprex (rBPI21) has been shown to be effective in thetreatment of severe pediatric meningococcemia. Of 26 patients enrolled in the trial, only one died. This 3.8% case-fatality rate compares favorably with a historical mortality rate of 20%. The company is currently conducting a Phase III trial of Neuprex in this indication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze